BACKGROUND: Present mechanical devices are unable to achieve recanalisation in up to 20-40% of large vessel occlusion strokes. We compared efficacy and safety of the Trevo Retriever, a new stent-like device, with its US Food and Drug Administration-cleared predecessor, the Merci Retriever. METHODS: In this open-label randomised controlled trial, we recruited patients at 26 sites in the USA and one in Spain. We included adults aged 18-85 years with angiographically confirmed large vessel occlusion strokes and US National Institutes of Health Stroke Scale (NIHSS) scores of 8-29 within 8 h of symptom onset. We randomly assigned patients (1:1) with sequentially numbered sealed envelopes to thrombectomy with Trevo or Merci devices. Randomisation was stratified by age (≤68 years vs 69-85 years) and NIHSS scores (≤18 vs 19-29) with alternating blocks of various sizes. The primary efficacy endpoint, assessed by an unmasked core laboratory, was thrombolysis in cerebral infarction (TICI) scores of 2 or greater reperfusion with the assigned device alone. The primary safety endpoint was a composite of procedure-related adverse events. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01270867. FINDINGS: Between Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever group and 90 patients to Merci Retriever group. 76 (86%) patients in the Trevo group and 54 (60%) in the Merci group met the primary endpoint after the assigned device was used (odds ratio 4·22, 95% CI 1·92-9·69; p(superiority)<0·0001). Incidence of the primary safety endpoint did not differ between groups (13 [15%] patients in the Trevo group vs 21 [23%] in the Merci group; p=0·1826). INTERPRETATION:Patients who have had large vessel occlusion strokes but are ineligible for (or refractory to) intravenous tissue plasminogen activator should be treated with the Trevo Retriever in preference to the Merci Retriever. FUNDING: Stryker Neurovascular.
RCT Entities:
BACKGROUND: Present mechanical devices are unable to achieve recanalisation in up to 20-40% of large vessel occlusion strokes. We compared efficacy and safety of the Trevo Retriever, a new stent-like device, with its US Food and Drug Administration-cleared predecessor, the Merci Retriever. METHODS: In this open-label randomised controlled trial, we recruited patients at 26 sites in the USA and one in Spain. We included adults aged 18-85 years with angiographically confirmed large vessel occlusion strokes and US National Institutes of Health Stroke Scale (NIHSS) scores of 8-29 within 8 h of symptom onset. We randomly assigned patients (1:1) with sequentially numbered sealed envelopes to thrombectomy with Trevo or Merci devices. Randomisation was stratified by age (≤68 years vs 69-85 years) and NIHSS scores (≤18 vs 19-29) with alternating blocks of various sizes. The primary efficacy endpoint, assessed by an unmasked core laboratory, was thrombolysis in cerebral infarction (TICI) scores of 2 or greater reperfusion with the assigned device alone. The primary safety endpoint was a composite of procedure-related adverse events. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01270867. FINDINGS: Between Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever group and 90 patients to Merci Retriever group. 76 (86%) patients in the Trevo group and 54 (60%) in the Merci group met the primary endpoint after the assigned device was used (odds ratio 4·22, 95% CI 1·92-9·69; p(superiority)<0·0001). Incidence of the primary safety endpoint did not differ between groups (13 [15%] patients in the Trevo group vs 21 [23%] in the Merci group; p=0·1826). INTERPRETATION:Patients who have had large vessel occlusion strokes but are ineligible for (or refractory to) intravenous tissue plasminogen activator should be treated with the Trevo Retriever in preference to the Merci Retriever. FUNDING: Stryker Neurovascular.
Authors: Nuno Mendonça; Alan Flores; Jorge Pagola; Marta Rubiera; David Rodríguez-Luna; M Angels De Miquel; Pere Cardona; Helena Quesada; Paloma Mora; José Alvarez-Sabín; Carlos Molina; Marc Ribó Journal: J Neuroimaging Date: 2011-12-30 Impact factor: 2.486
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Luis San Román; Victor Obach; Jordi Blasco; Juan Macho; Antonio Lopez; Xabier Urra; Alejandro Tomasello; Alvaro Cervera; Sergio Amaro; Joan Perandreu; Jordi Branera; Sebastián Capurro; Laura Oleaga; Angel Chamorro Journal: Stroke Date: 2012-03-22 Impact factor: 7.914
Authors: J R Marler; B C Tilley; M Lu; T G Brott; P C Lyden; J C Grotta; J P Broderick; S R Levine; M P Frankel; S H Horowitz; E C Haley; C A Lewandowski; T P Kwiatkowski Journal: Neurology Date: 2000-12-12 Impact factor: 9.910
Authors: Randall T Higashida; Anthony J Furlan; Heidi Roberts; Thomas Tomsick; Buddy Connors; John Barr; William Dillon; Steven Warach; Joseph Broderick; Barbara Tilley; David Sacks Journal: Stroke Date: 2003-07-17 Impact factor: 7.914
Authors: Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: C Kabbasch; A Mpotsaris; T Liebig; M Söderman; M Holtmannspötter; M Cronqvist; J Thornton; V Mendes Pereira; T Andersson Journal: Clin Neuroradiol Date: 2014-11-01 Impact factor: 3.649
Authors: U Yilmaz; S Walter; H Körner; P Papanagiotou; C Roth; A Simgen; S Behnke; A Ragoschke-Schumm; K Fassbender; W Reith Journal: Clin Neuroradiol Date: 2014-02-14 Impact factor: 3.649
Authors: Mayank Goyal; Mohammed A Almekhlafi; Liqiong Fan; Bijoy K Menon; Andrew M Demchuk; Sharon D Yeatts; Michael D Hill; Thomas Tomsick; Pooja Khatri; Osama O Zaidat; Edward C Jauch; Muneer Eesa; Tudor G Jovin; Joseph P Broderick Journal: Circulation Date: 2014-05-09 Impact factor: 29.690
Authors: M A Almekhlafi; A Davalos; A Bonafe; R Chapot; J Gralla; V M Pereira; M Goyal Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825
Authors: Yin C Hu; Chandril Chugh; Dhruve Jeevan; John L Gillick; Stephan Marks; Michael F Stiefel Journal: Childs Nerv Syst Date: 2013-11-10 Impact factor: 1.475